Search
Dapagliflozin
go.drugbank.com/drugs/DB06292ApprovedInvestigationalDapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. … [A6757] Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents.
Synonyms: (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triolMixtures: XIGLIF-M, PLEMTUM-MBIIB015
go.drugbank.com/drugs/DB06304InvestigationalBIIB015 is a humanized, IgG1 [immunoglobulin G 1], DM4-Conjugated, anti-cripto, monoclonal antibody. It has been investigated for the treatment of subjects with relapsed or refractory solid tumours.
SGX-523
go.drugbank.com/drugs/DB06314InvestigationalA MET receptor tyrosine kinase inhibitor.
Synonyms: 6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinolineCategories: Heterocyclic Compounds, 1-RingElotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalElotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. … Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.
XmAb 2513
go.drugbank.com/drugs/DB06324InvestigationalXmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types.